nodes	percent_of_prediction	percent_of_DWPC	metapath
Oxaprozin—PTGS2—urinary bladder cancer	0.486	1	CbGaD
Oxaprozin—PTGS2—Cisplatin—urinary bladder cancer	0.0774	0.282	CbGbCtD
Oxaprozin—PTGS2—Etoposide—urinary bladder cancer	0.076	0.277	CbGbCtD
Oxaprozin—PTGS1—Etoposide—urinary bladder cancer	0.0642	0.234	CbGbCtD
Oxaprozin—CYP2C9—Fluorouracil—urinary bladder cancer	0.031	0.113	CbGbCtD
Oxaprozin—CYP2C9—Cisplatin—urinary bladder cancer	0.0263	0.0957	CbGbCtD
Oxaprozin—CYP2C9—urine—urinary bladder cancer	0.00158	0.207	CbGeAlD
Oxaprozin—Benzphetamine—POR—urinary bladder cancer	0.00127	0.282	CrCbGaD
Oxaprozin—Flurbiprofen—UGT2B7—urinary bladder cancer	0.00124	0.276	CrCbGaD
Oxaprozin—Carbamazepine—UGT2B7—urinary bladder cancer	0.00109	0.242	CrCbGaD
Oxaprozin—PTGS1—prostate gland—urinary bladder cancer	0.000519	0.068	CbGeAlD
Oxaprozin—PTGS2—prostate gland—urinary bladder cancer	0.000496	0.065	CbGeAlD
Oxaprozin—PTGS1—Biological oxidations—GSTO2—urinary bladder cancer	0.000447	0.0115	CbGpPWpGaD
Oxaprozin—PTGS1—Biological oxidations—NAT1—urinary bladder cancer	0.000447	0.0115	CbGpPWpGaD
Oxaprozin—PTGS2—Aryl Hydrocarbon Receptor—HPGDS—urinary bladder cancer	0.000446	0.0115	CbGpPWpGaD
Oxaprozin—CYP2C9—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.000444	0.0114	CbGpPWpGaD
Oxaprozin—PTGS1—seminal vesicle—urinary bladder cancer	0.000439	0.0575	CbGeAlD
Oxaprozin—Fenbufen—PTGS2—urinary bladder cancer	0.000437	0.0973	CrCbGaD
Oxaprozin—PTGS2—seminal vesicle—urinary bladder cancer	0.000419	0.055	CbGeAlD
Oxaprozin—PTGS2—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.000418	0.0108	CbGpPWpGaD
Oxaprozin—PTGS1—Biological oxidations—UGT2B7—urinary bladder cancer	0.000409	0.0105	CbGpPWpGaD
Oxaprozin—PTGS1—Overview of nanoparticle effects—PTGS2—urinary bladder cancer	0.000397	0.0102	CbGpPWpGaD
Oxaprozin—PTGS1—Overview of nanoparticle effects—CXCL8—urinary bladder cancer	0.000385	0.00993	CbGpPWpGaD
Oxaprozin—PTGS1—epithelium—urinary bladder cancer	0.000381	0.0499	CbGeAlD
Oxaprozin—PTGS1—Biological oxidations—CYP4B1—urinary bladder cancer	0.000368	0.00948	CbGpPWpGaD
Oxaprozin—PTGS1—smooth muscle tissue—urinary bladder cancer	0.000367	0.0481	CbGeAlD
Oxaprozin—CYP2C9—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000364	0.00938	CbGpPWpGaD
Oxaprozin—PTGS2—epithelium—urinary bladder cancer	0.000364	0.0477	CbGeAlD
Oxaprozin—CYP2C9—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000363	0.00935	CbGpPWpGaD
Oxaprozin—PTGS2—Aryl Hydrocarbon Receptor—NQO1—urinary bladder cancer	0.00036	0.00927	CbGpPWpGaD
Oxaprozin—PTGS1—renal system—urinary bladder cancer	0.000353	0.0463	CbGeAlD
Oxaprozin—PTGS2—smooth muscle tissue—urinary bladder cancer	0.000351	0.046	CbGeAlD
Oxaprozin—PTGS2—S1P1 pathway—RHOA—urinary bladder cancer	0.000349	0.00898	CbGpPWpGaD
Oxaprozin—PTGS2—renal system—urinary bladder cancer	0.000338	0.0443	CbGeAlD
Oxaprozin—PTGS2—urethra—urinary bladder cancer	0.000332	0.0435	CbGeAlD
Oxaprozin—PTGS1—Selenium Micronutrient Network—MPO—urinary bladder cancer	0.000331	0.00852	CbGpPWpGaD
Oxaprozin—PTGS1—Eicosanoid Synthesis—PTGS2—urinary bladder cancer	0.00033	0.00849	CbGpPWpGaD
Oxaprozin—PTGS2—C-MYB transcription factor network—BIRC3—urinary bladder cancer	0.000318	0.0082	CbGpPWpGaD
Oxaprozin—PTGS1—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000311	0.00802	CbGpPWpGaD
Oxaprozin—CYP2C9—female reproductive system—urinary bladder cancer	0.00031	0.0406	CbGeAlD
Oxaprozin—PTGS2—Overview of nanoparticle effects—CXCL8—urinary bladder cancer	0.000306	0.00788	CbGpPWpGaD
Oxaprozin—PTGS1—female reproductive system—urinary bladder cancer	0.000283	0.0371	CbGeAlD
Oxaprozin—CYP2C9—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.000277	0.00712	CbGpPWpGaD
Oxaprozin—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—urinary bladder cancer	0.000276	0.0071	CbGpPWpGaD
Oxaprozin—PTGS2—C-MYB transcription factor network—MPO—urinary bladder cancer	0.000272	0.00702	CbGpPWpGaD
Oxaprozin—PTGS2—female reproductive system—urinary bladder cancer	0.000271	0.0355	CbGeAlD
Oxaprozin—PTGS2—Signaling mediated by p38-alpha and p38-beta—ESR1—urinary bladder cancer	0.00027	0.00695	CbGpPWpGaD
Oxaprozin—PTGS1—Overview of nanoparticle effects—TNF—urinary bladder cancer	0.000268	0.00691	CbGpPWpGaD
Oxaprozin—PTGS2—Selenium Micronutrient Network—MPO—urinary bladder cancer	0.000262	0.00676	CbGpPWpGaD
Oxaprozin—PTGS1—vagina—urinary bladder cancer	0.000256	0.0336	CbGeAlD
Oxaprozin—Phenylbutazone—PTGS2—urinary bladder cancer	0.000251	0.0559	CrCbGaD
Oxaprozin—CYP2C9—Biological oxidations—GSTZ1—urinary bladder cancer	0.000248	0.00639	CbGpPWpGaD
Oxaprozin—PTGS2—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000247	0.00637	CbGpPWpGaD
Oxaprozin—PTGS1—Biological oxidations—NAT2—urinary bladder cancer	0.000245	0.00631	CbGpPWpGaD
Oxaprozin—PTGS2—vagina—urinary bladder cancer	0.000245	0.0321	CbGeAlD
Oxaprozin—CYP2C9—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000245	0.0063	CbGpPWpGaD
Oxaprozin—CYP2C9—Biological oxidations—GSTO2—urinary bladder cancer	0.000235	0.00605	CbGpPWpGaD
Oxaprozin—CYP2C9—Biological oxidations—NAT1—urinary bladder cancer	0.000235	0.00605	CbGpPWpGaD
Oxaprozin—CYP2C9—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000232	0.00597	CbGpPWpGaD
Oxaprozin—PTGS2—Aryl Hydrocarbon Receptor—ESR1—urinary bladder cancer	0.000217	0.00558	CbGpPWpGaD
Oxaprozin—CYP2C9—Biological oxidations—UGT2B7—urinary bladder cancer	0.000215	0.00554	CbGpPWpGaD
Oxaprozin—PTGS2—Overview of nanoparticle effects—TNF—urinary bladder cancer	0.000213	0.00549	CbGpPWpGaD
Oxaprozin—CYP2C9—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000212	0.00546	CbGpPWpGaD
Oxaprozin—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—urinary bladder cancer	0.000208	0.00537	CbGpPWpGaD
Oxaprozin—PTGS1—Selenium Micronutrient Network—SOD2—urinary bladder cancer	0.000208	0.00535	CbGpPWpGaD
Oxaprozin—Flurbiprofen—PTGS2—urinary bladder cancer	0.000205	0.0456	CrCbGaD
Oxaprozin—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CDK4—urinary bladder cancer	0.000204	0.00524	CbGpPWpGaD
Oxaprozin—PTGS1—Selenium Micronutrient Network—GPX1—urinary bladder cancer	0.000198	0.0051	CbGpPWpGaD
Oxaprozin—PTGS1—Biological oxidations—HPGDS—urinary bladder cancer	0.000196	0.00504	CbGpPWpGaD
Oxaprozin—CYP2C9—Biological oxidations—CYP4B1—urinary bladder cancer	0.000194	0.00499	CbGpPWpGaD
Oxaprozin—CYP2C9—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000191	0.00492	CbGpPWpGaD
Oxaprozin—PTGS1—Biological oxidations—GSTT1—urinary bladder cancer	0.00019	0.00489	CbGpPWpGaD
Oxaprozin—PTGS2—Aryl Hydrocarbon Receptor—RB1—urinary bladder cancer	0.000189	0.00487	CbGpPWpGaD
Oxaprozin—PTGS2—Integrated Pancreatic Cancer Pathway—LIG1—urinary bladder cancer	0.000187	0.00483	CbGpPWpGaD
Oxaprozin—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—urinary bladder cancer	0.000185	0.00476	CbGpPWpGaD
Oxaprozin—PTGS1—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000183	0.00472	CbGpPWpGaD
Oxaprozin—PTGS1—Selenium Micronutrient Network—MTHFR—urinary bladder cancer	0.000183	0.00471	CbGpPWpGaD
Oxaprozin—Toxic epidermal necrolysis—Doxorubicin—urinary bladder cancer	0.000182	0.000968	CcSEcCtD
Oxaprozin—Decreased appetite—Cisplatin—urinary bladder cancer	0.000182	0.000966	CcSEcCtD
Oxaprozin—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000182	0.000966	CcSEcCtD
Oxaprozin—Pneumonia—Methotrexate—urinary bladder cancer	0.000181	0.000962	CcSEcCtD
Oxaprozin—Drowsiness—Methotrexate—urinary bladder cancer	0.00018	0.000956	CcSEcCtD
Oxaprozin—Pancytopenia—Epirubicin—urinary bladder cancer	0.000179	0.000953	CcSEcCtD
Oxaprozin—Hypotension—Etoposide—urinary bladder cancer	0.000179	0.000951	CcSEcCtD
Oxaprozin—Gastritis—Doxorubicin—urinary bladder cancer	0.000179	0.000951	CcSEcCtD
Oxaprozin—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	0.000178	0.000948	CcSEcCtD
Oxaprozin—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000177	0.000943	CcSEcCtD
Oxaprozin—Renal failure—Methotrexate—urinary bladder cancer	0.000177	0.00094	CcSEcCtD
Oxaprozin—Dysuria—Epirubicin—urinary bladder cancer	0.000176	0.000939	CcSEcCtD
Oxaprozin—Dizziness—Thiotepa—urinary bladder cancer	0.000176	0.000937	CcSEcCtD
Oxaprozin—Stomatitis—Methotrexate—urinary bladder cancer	0.000175	0.000932	CcSEcCtD
Oxaprozin—Urticaria—Fluorouracil—urinary bladder cancer	0.000175	0.000931	CcSEcCtD
Oxaprozin—Conjunctivitis—Methotrexate—urinary bladder cancer	0.000175	0.00093	CcSEcCtD
Oxaprozin—Asthma—Doxorubicin—urinary bladder cancer	0.000175	0.000929	CcSEcCtD
Oxaprozin—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000174	0.000927	CcSEcCtD
Oxaprozin—Eosinophilia—Doxorubicin—urinary bladder cancer	0.000173	0.00092	CcSEcCtD
Oxaprozin—Photosensitivity reaction—Epirubicin—urinary bladder cancer	0.000172	0.000916	CcSEcCtD
Oxaprozin—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000172	0.000916	CcSEcCtD
Oxaprozin—Paraesthesia—Etoposide—urinary bladder cancer	0.000172	0.000914	CcSEcCtD
Oxaprozin—Haematuria—Methotrexate—urinary bladder cancer	0.000171	0.000912	CcSEcCtD
Oxaprozin—Pancreatitis—Doxorubicin—urinary bladder cancer	0.000171	0.000911	CcSEcCtD
Oxaprozin—Dyspnoea—Etoposide—urinary bladder cancer	0.000171	0.000908	CcSEcCtD
Oxaprozin—PTGS2—C-MYB transcription factor network—NCOR1—urinary bladder cancer	0.00017	0.00439	CbGpPWpGaD
Oxaprozin—PTGS2—C-MYB transcription factor network—GSTM1—urinary bladder cancer	0.00017	0.00439	CbGpPWpGaD
Oxaprozin—Hyperglycaemia—Epirubicin—urinary bladder cancer	0.00017	0.000905	CcSEcCtD
Oxaprozin—Somnolence—Etoposide—urinary bladder cancer	0.00017	0.000905	CcSEcCtD
Oxaprozin—Vomiting—Thiotepa—urinary bladder cancer	0.000169	0.000901	CcSEcCtD
Oxaprozin—Pneumonia—Epirubicin—urinary bladder cancer	0.000169	0.0009	CcSEcCtD
Oxaprozin—Drowsiness—Epirubicin—urinary bladder cancer	0.000168	0.000895	CcSEcCtD
Oxaprozin—Rash—Thiotepa—urinary bladder cancer	0.000168	0.000894	CcSEcCtD
Oxaprozin—Dermatitis—Thiotepa—urinary bladder cancer	0.000168	0.000893	CcSEcCtD
Oxaprozin—Agranulocytosis—Methotrexate—urinary bladder cancer	0.000168	0.000892	CcSEcCtD
Oxaprozin—Headache—Thiotepa—urinary bladder cancer	0.000167	0.000888	CcSEcCtD
Oxaprozin—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.000167	0.000887	CcSEcCtD
Oxaprozin—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000167	0.00429	CbGpPWpGaD
Oxaprozin—Decreased appetite—Etoposide—urinary bladder cancer	0.000166	0.000885	CcSEcCtD
Oxaprozin—Pancytopenia—Doxorubicin—urinary bladder cancer	0.000166	0.000882	CcSEcCtD
Oxaprozin—PTGS1—lymph node—urinary bladder cancer	0.000166	0.0217	CbGeAlD
Oxaprozin—Renal failure—Epirubicin—urinary bladder cancer	0.000165	0.00088	CcSEcCtD
Oxaprozin—Body temperature increased—Cisplatin—urinary bladder cancer	0.000165	0.000879	CcSEcCtD
Oxaprozin—PTGS2—Selenium Micronutrient Network—SOD2—urinary bladder cancer	0.000165	0.00424	CbGpPWpGaD
Oxaprozin—Stomatitis—Epirubicin—urinary bladder cancer	0.000164	0.000872	CcSEcCtD
Oxaprozin—Jaundice—Epirubicin—urinary bladder cancer	0.000164	0.000872	CcSEcCtD
Oxaprozin—Constipation—Etoposide—urinary bladder cancer	0.000164	0.000871	CcSEcCtD
Oxaprozin—CYP2C9—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000164	0.00422	CbGpPWpGaD
Oxaprozin—Conjunctivitis—Epirubicin—urinary bladder cancer	0.000164	0.00087	CcSEcCtD
Oxaprozin—Dysuria—Doxorubicin—urinary bladder cancer	0.000163	0.000868	CcSEcCtD
Oxaprozin—Haemoglobin—Methotrexate—urinary bladder cancer	0.000162	0.000863	CcSEcCtD
Oxaprozin—Haemorrhage—Methotrexate—urinary bladder cancer	0.000161	0.000858	CcSEcCtD
Oxaprozin—Hepatitis—Methotrexate—urinary bladder cancer	0.000161	0.000858	CcSEcCtD
Oxaprozin—Asthenia—Gemcitabine—urinary bladder cancer	0.000161	0.000856	CcSEcCtD
Oxaprozin—Haematuria—Epirubicin—urinary bladder cancer	0.00016	0.000853	CcSEcCtD
Oxaprozin—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.000159	0.000848	CcSEcCtD
Oxaprozin—Pruritus—Gemcitabine—urinary bladder cancer	0.000159	0.000844	CcSEcCtD
Oxaprozin—Nausea—Thiotepa—urinary bladder cancer	0.000158	0.000842	CcSEcCtD
Oxaprozin—PTGS2—lymph node—urinary bladder cancer	0.000158	0.0207	CbGeAlD
Oxaprozin—Sinusitis—Epirubicin—urinary bladder cancer	0.000158	0.00084	CcSEcCtD
Oxaprozin—Feeling abnormal—Etoposide—urinary bladder cancer	0.000158	0.000839	CcSEcCtD
Oxaprozin—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.000158	0.000838	CcSEcCtD
Oxaprozin—PTGS2—Selenium Micronutrient Network—GPX1—urinary bladder cancer	0.000157	0.00405	CbGpPWpGaD
Oxaprozin—Agranulocytosis—Epirubicin—urinary bladder cancer	0.000157	0.000835	CcSEcCtD
Oxaprozin—Pneumonia—Doxorubicin—urinary bladder cancer	0.000157	0.000833	CcSEcCtD
Oxaprozin—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000157	0.000833	CcSEcCtD
Oxaprozin—Pruritus—Fluorouracil—urinary bladder cancer	0.000156	0.00083	CcSEcCtD
Oxaprozin—Drowsiness—Doxorubicin—urinary bladder cancer	0.000156	0.000828	CcSEcCtD
Oxaprozin—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.000154	0.000821	CcSEcCtD
Oxaprozin—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000153	0.000816	CcSEcCtD
Oxaprozin—Renal failure—Doxorubicin—urinary bladder cancer	0.000153	0.000814	CcSEcCtD
Oxaprozin—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000153	0.000812	CcSEcCtD
Oxaprozin—Urticaria—Etoposide—urinary bladder cancer	0.000152	0.000809	CcSEcCtD
Oxaprozin—Haemoglobin—Epirubicin—urinary bladder cancer	0.000152	0.000807	CcSEcCtD
Oxaprozin—Jaundice—Doxorubicin—urinary bladder cancer	0.000152	0.000807	CcSEcCtD
Oxaprozin—Stomatitis—Doxorubicin—urinary bladder cancer	0.000152	0.000807	CcSEcCtD
Oxaprozin—Abdominal pain—Etoposide—urinary bladder cancer	0.000151	0.000805	CcSEcCtD
Oxaprozin—Body temperature increased—Etoposide—urinary bladder cancer	0.000151	0.000805	CcSEcCtD
Oxaprozin—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000151	0.000805	CcSEcCtD
Oxaprozin—Haemorrhage—Epirubicin—urinary bladder cancer	0.000151	0.000803	CcSEcCtD
Oxaprozin—Hepatitis—Epirubicin—urinary bladder cancer	0.000151	0.000803	CcSEcCtD
Oxaprozin—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000151	0.000802	CcSEcCtD
Oxaprozin—Tinnitus—Methotrexate—urinary bladder cancer	0.000151	0.0008	CcSEcCtD
Oxaprozin—Asthenia—Cisplatin—urinary bladder cancer	0.00015	0.000797	CcSEcCtD
Oxaprozin—Haematuria—Doxorubicin—urinary bladder cancer	0.000148	0.00079	CcSEcCtD
Oxaprozin—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—urinary bladder cancer	0.000146	0.00377	CbGpPWpGaD
Oxaprozin—Sinusitis—Doxorubicin—urinary bladder cancer	0.000146	0.000777	CcSEcCtD
Oxaprozin—Dizziness—Fluorouracil—urinary bladder cancer	0.000146	0.000775	CcSEcCtD
Oxaprozin—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000145	0.000773	CcSEcCtD
Oxaprozin—PTGS2—Selenium Micronutrient Network—MTHFR—urinary bladder cancer	0.000145	0.00374	CbGpPWpGaD
Oxaprozin—Diarrhoea—Cisplatin—urinary bladder cancer	0.000143	0.00076	CcSEcCtD
Oxaprozin—PTGS2—Integrated Pancreatic Cancer Pathway—HPGDS—urinary bladder cancer	0.000143	0.00368	CbGpPWpGaD
Oxaprozin—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000143	0.00076	CcSEcCtD
Oxaprozin—Alopecia—Methotrexate—urinary bladder cancer	0.000143	0.000759	CcSEcCtD
Oxaprozin—Vomiting—Gemcitabine—urinary bladder cancer	0.000143	0.000758	CcSEcCtD
Oxaprozin—PTGS2—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	0.000142	0.00366	CbGpPWpGaD
Oxaprozin—Rash—Gemcitabine—urinary bladder cancer	0.000141	0.000752	CcSEcCtD
Oxaprozin—PTGS1—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000141	0.00364	CbGpPWpGaD
Oxaprozin—Dermatitis—Gemcitabine—urinary bladder cancer	0.000141	0.000751	CcSEcCtD
Oxaprozin—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—urinary bladder cancer	0.000141	0.00363	CbGpPWpGaD
Oxaprozin—Tinnitus—Epirubicin—urinary bladder cancer	0.000141	0.000749	CcSEcCtD
Oxaprozin—Haemoglobin—Doxorubicin—urinary bladder cancer	0.00014	0.000747	CcSEcCtD
Oxaprozin—Headache—Gemcitabine—urinary bladder cancer	0.00014	0.000747	CcSEcCtD
Oxaprozin—Vomiting—Fluorouracil—urinary bladder cancer	0.00014	0.000745	CcSEcCtD
Oxaprozin—Haemorrhage—Doxorubicin—urinary bladder cancer	0.00014	0.000743	CcSEcCtD
Oxaprozin—Hepatitis—Doxorubicin—urinary bladder cancer	0.00014	0.000743	CcSEcCtD
Oxaprozin—Rash—Fluorouracil—urinary bladder cancer	0.000139	0.000739	CcSEcCtD
Oxaprozin—Dermatitis—Fluorouracil—urinary bladder cancer	0.000139	0.000739	CcSEcCtD
Oxaprozin—Headache—Fluorouracil—urinary bladder cancer	0.000138	0.000734	CcSEcCtD
Oxaprozin—Dysgeusia—Methotrexate—urinary bladder cancer	0.000138	0.000732	CcSEcCtD
Oxaprozin—Asthenia—Etoposide—urinary bladder cancer	0.000137	0.000731	CcSEcCtD
Oxaprozin—PTGS2—Aryl Hydrocarbon Receptor—CDKN1A—urinary bladder cancer	0.000136	0.0035	CbGpPWpGaD
Oxaprozin—Pruritus—Etoposide—urinary bladder cancer	0.000135	0.00072	CcSEcCtD
Oxaprozin—Arrhythmia—Epirubicin—urinary bladder cancer	0.000135	0.000718	CcSEcCtD
Oxaprozin—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—urinary bladder cancer	0.000135	0.00347	CbGpPWpGaD
Oxaprozin—Alopecia—Epirubicin—urinary bladder cancer	0.000133	0.00071	CcSEcCtD
Oxaprozin—Nausea—Gemcitabine—urinary bladder cancer	0.000133	0.000708	CcSEcCtD
Oxaprozin—Vomiting—Cisplatin—urinary bladder cancer	0.000133	0.000707	CcSEcCtD
Oxaprozin—Vision blurred—Methotrexate—urinary bladder cancer	0.000132	0.000704	CcSEcCtD
Oxaprozin—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000132	0.000703	CcSEcCtD
Oxaprozin—Rash—Cisplatin—urinary bladder cancer	0.000132	0.000701	CcSEcCtD
Oxaprozin—Dermatitis—Cisplatin—urinary bladder cancer	0.000132	0.0007	CcSEcCtD
Oxaprozin—PTGS1—Biological oxidations—GSTP1—urinary bladder cancer	0.000132	0.00339	CbGpPWpGaD
Oxaprozin—Diarrhoea—Etoposide—urinary bladder cancer	0.000131	0.000697	CcSEcCtD
Oxaprozin—Nausea—Fluorouracil—urinary bladder cancer	0.000131	0.000696	CcSEcCtD
Oxaprozin—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.00013	0.000693	CcSEcCtD
Oxaprozin—Tinnitus—Doxorubicin—urinary bladder cancer	0.00013	0.000693	CcSEcCtD
Oxaprozin—Anaemia—Methotrexate—urinary bladder cancer	0.00013	0.000691	CcSEcCtD
Oxaprozin—Flatulence—Epirubicin—urinary bladder cancer	0.00013	0.000689	CcSEcCtD
Oxaprozin—PTGS2—Aryl Hydrocarbon Receptor—EP300—urinary bladder cancer	0.000129	0.00333	CbGpPWpGaD
Oxaprozin—Tension—Epirubicin—urinary bladder cancer	0.000129	0.000686	CcSEcCtD
Oxaprozin—Dysgeusia—Epirubicin—urinary bladder cancer	0.000129	0.000685	CcSEcCtD
Oxaprozin—CYP2C9—Biological oxidations—NAT2—urinary bladder cancer	0.000129	0.00332	CbGpPWpGaD
Oxaprozin—Nervousness—Epirubicin—urinary bladder cancer	0.000128	0.000679	CcSEcCtD
Oxaprozin—CYP2C9—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000127	0.00327	CbGpPWpGaD
Oxaprozin—Malaise—Methotrexate—urinary bladder cancer	0.000127	0.000674	CcSEcCtD
Oxaprozin—Dizziness—Etoposide—urinary bladder cancer	0.000127	0.000673	CcSEcCtD
Oxaprozin—Vertigo—Methotrexate—urinary bladder cancer	0.000126	0.000671	CcSEcCtD
Oxaprozin—Leukopenia—Methotrexate—urinary bladder cancer	0.000126	0.000669	CcSEcCtD
Oxaprozin—PTGS2—Aryl Hydrocarbon Receptor—SRC—urinary bladder cancer	0.000126	0.00324	CbGpPWpGaD
Oxaprozin—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000125	0.000664	CcSEcCtD
Oxaprozin—Nausea—Cisplatin—urinary bladder cancer	0.000124	0.00066	CcSEcCtD
Oxaprozin—Vision blurred—Epirubicin—urinary bladder cancer	0.000124	0.000659	CcSEcCtD
Oxaprozin—Alopecia—Doxorubicin—urinary bladder cancer	0.000124	0.000657	CcSEcCtD
Oxaprozin—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000122	0.000649	CcSEcCtD
Oxaprozin—Convulsion—Methotrexate—urinary bladder cancer	0.000122	0.000647	CcSEcCtD
Oxaprozin—Vomiting—Etoposide—urinary bladder cancer	0.000122	0.000647	CcSEcCtD
Oxaprozin—Anaemia—Epirubicin—urinary bladder cancer	0.000122	0.000646	CcSEcCtD
Oxaprozin—PTGS1—Biological oxidations—GSTM1—urinary bladder cancer	0.000121	0.00312	CbGpPWpGaD
Oxaprozin—Rash—Etoposide—urinary bladder cancer	0.000121	0.000642	CcSEcCtD
Oxaprozin—Dermatitis—Etoposide—urinary bladder cancer	0.000121	0.000641	CcSEcCtD
Oxaprozin—Headache—Etoposide—urinary bladder cancer	0.00012	0.000638	CcSEcCtD
Oxaprozin—Flatulence—Doxorubicin—urinary bladder cancer	0.00012	0.000638	CcSEcCtD
Oxaprozin—Tension—Doxorubicin—urinary bladder cancer	0.000119	0.000635	CcSEcCtD
Oxaprozin—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000119	0.000634	CcSEcCtD
Oxaprozin—Malaise—Epirubicin—urinary bladder cancer	0.000119	0.000631	CcSEcCtD
Oxaprozin—Discomfort—Methotrexate—urinary bladder cancer	0.000118	0.000629	CcSEcCtD
Oxaprozin—Nervousness—Doxorubicin—urinary bladder cancer	0.000118	0.000629	CcSEcCtD
Oxaprozin—Vertigo—Epirubicin—urinary bladder cancer	0.000118	0.000628	CcSEcCtD
Oxaprozin—Syncope—Epirubicin—urinary bladder cancer	0.000118	0.000627	CcSEcCtD
Oxaprozin—Leukopenia—Epirubicin—urinary bladder cancer	0.000118	0.000626	CcSEcCtD
Oxaprozin—PTGS2—C-MYB transcription factor network—CREBBP—urinary bladder cancer	0.000117	0.00302	CbGpPWpGaD
Oxaprozin—PTGS1—Selenium Micronutrient Network—PTGS2—urinary bladder cancer	0.000117	0.003	CbGpPWpGaD
Oxaprozin—Palpitations—Epirubicin—urinary bladder cancer	0.000116	0.000618	CcSEcCtD
Oxaprozin—Confusional state—Methotrexate—urinary bladder cancer	0.000116	0.000615	CcSEcCtD
Oxaprozin—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000116	0.000615	CcSEcCtD
Oxaprozin—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—urinary bladder cancer	0.000115	0.00297	CbGpPWpGaD
Oxaprozin—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000115	0.00061	CcSEcCtD
Oxaprozin—Vision blurred—Doxorubicin—urinary bladder cancer	0.000115	0.00061	CcSEcCtD
Oxaprozin—PTGS2—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	0.000114	0.00295	CbGpPWpGaD
Oxaprozin—Convulsion—Epirubicin—urinary bladder cancer	0.000114	0.000606	CcSEcCtD
Oxaprozin—Infection—Methotrexate—urinary bladder cancer	0.000114	0.000606	CcSEcCtD
Oxaprozin—Nausea—Etoposide—urinary bladder cancer	0.000114	0.000605	CcSEcCtD
Oxaprozin—Hypertension—Epirubicin—urinary bladder cancer	0.000114	0.000604	CcSEcCtD
Oxaprozin—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000113	0.0006	CcSEcCtD
Oxaprozin—PTGS2—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	0.000113	0.0029	CbGpPWpGaD
Oxaprozin—Anaemia—Doxorubicin—urinary bladder cancer	0.000112	0.000598	CcSEcCtD
Oxaprozin—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000112	0.000597	CcSEcCtD
Oxaprozin—PTGS2—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000112	0.00289	CbGpPWpGaD
Oxaprozin—Anxiety—Epirubicin—urinary bladder cancer	0.000112	0.000593	CcSEcCtD
Oxaprozin—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000111	0.00059	CcSEcCtD
Oxaprozin—Discomfort—Epirubicin—urinary bladder cancer	0.000111	0.000588	CcSEcCtD
Oxaprozin—PTGS2—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	0.00011	0.00284	CbGpPWpGaD
Oxaprozin—Malaise—Doxorubicin—urinary bladder cancer	0.00011	0.000584	CcSEcCtD
Oxaprozin—Dry mouth—Epirubicin—urinary bladder cancer	0.000109	0.000582	CcSEcCtD
Oxaprozin—Vertigo—Doxorubicin—urinary bladder cancer	0.000109	0.000581	CcSEcCtD
Oxaprozin—Anorexia—Methotrexate—urinary bladder cancer	0.000109	0.000581	CcSEcCtD
Oxaprozin—Syncope—Doxorubicin—urinary bladder cancer	0.000109	0.00058	CcSEcCtD
Oxaprozin—Leukopenia—Doxorubicin—urinary bladder cancer	0.000109	0.000579	CcSEcCtD
Oxaprozin—Confusional state—Epirubicin—urinary bladder cancer	0.000108	0.000576	CcSEcCtD
Oxaprozin—Palpitations—Doxorubicin—urinary bladder cancer	0.000108	0.000572	CcSEcCtD
Oxaprozin—Oedema—Epirubicin—urinary bladder cancer	0.000107	0.000571	CcSEcCtD
Oxaprozin—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000107	0.000571	CcSEcCtD
Oxaprozin—Hypotension—Methotrexate—urinary bladder cancer	0.000107	0.00057	CcSEcCtD
Oxaprozin—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000107	0.000569	CcSEcCtD
Oxaprozin—Infection—Epirubicin—urinary bladder cancer	0.000107	0.000567	CcSEcCtD
Oxaprozin—Shock—Epirubicin—urinary bladder cancer	0.000106	0.000562	CcSEcCtD
Oxaprozin—Convulsion—Doxorubicin—urinary bladder cancer	0.000105	0.000561	CcSEcCtD
Oxaprozin—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000105	0.000559	CcSEcCtD
Oxaprozin—Hypertension—Doxorubicin—urinary bladder cancer	0.000105	0.000559	CcSEcCtD
Oxaprozin—PTGS2—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	0.000105	0.0027	CbGpPWpGaD
Oxaprozin—Tachycardia—Epirubicin—urinary bladder cancer	0.000105	0.000557	CcSEcCtD
Oxaprozin—PTGS2—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	0.000104	0.00268	CbGpPWpGaD
Oxaprozin—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000104	0.000552	CcSEcCtD
Oxaprozin—Insomnia—Methotrexate—urinary bladder cancer	0.000104	0.000552	CcSEcCtD
Oxaprozin—Anxiety—Doxorubicin—urinary bladder cancer	0.000103	0.000549	CcSEcCtD
Oxaprozin—Paraesthesia—Methotrexate—urinary bladder cancer	0.000103	0.000548	CcSEcCtD
Oxaprozin—CYP2C9—Biological oxidations—HPGDS—urinary bladder cancer	0.000103	0.00265	CbGpPWpGaD
Oxaprozin—PTGS2—C-MYB transcription factor network—CDKN2A—urinary bladder cancer	0.000103	0.00265	CbGpPWpGaD
Oxaprozin—PTGS2—Spinal Cord Injury—CDK4—urinary bladder cancer	0.000102	0.00264	CbGpPWpGaD
Oxaprozin—Discomfort—Doxorubicin—urinary bladder cancer	0.000102	0.000544	CcSEcCtD
Oxaprozin—Anorexia—Epirubicin—urinary bladder cancer	0.000102	0.000544	CcSEcCtD
Oxaprozin—Dyspnoea—Methotrexate—urinary bladder cancer	0.000102	0.000544	CcSEcCtD
Oxaprozin—Somnolence—Methotrexate—urinary bladder cancer	0.000102	0.000542	CcSEcCtD
Oxaprozin—Dry mouth—Doxorubicin—urinary bladder cancer	0.000101	0.000539	CcSEcCtD
Oxaprozin—Dyspepsia—Methotrexate—urinary bladder cancer	0.000101	0.000537	CcSEcCtD
Oxaprozin—Hypotension—Epirubicin—urinary bladder cancer	0.0001	0.000533	CcSEcCtD
Oxaprozin—Confusional state—Doxorubicin—urinary bladder cancer	0.0001	0.000533	CcSEcCtD
Oxaprozin—CYP2C9—Biological oxidations—GSTT1—urinary bladder cancer	9.98e-05	0.00257	CbGpPWpGaD
Oxaprozin—Decreased appetite—Methotrexate—urinary bladder cancer	9.97e-05	0.00053	CcSEcCtD
Oxaprozin—Oedema—Doxorubicin—urinary bladder cancer	9.93e-05	0.000528	CcSEcCtD
Oxaprozin—Anaphylactic shock—Doxorubicin—urinary bladder cancer	9.93e-05	0.000528	CcSEcCtD
Oxaprozin—Infection—Doxorubicin—urinary bladder cancer	9.87e-05	0.000525	CcSEcCtD
Oxaprozin—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—urinary bladder cancer	9.82e-05	0.00253	CbGpPWpGaD
Oxaprozin—Shock—Doxorubicin—urinary bladder cancer	9.77e-05	0.00052	CcSEcCtD
Oxaprozin—Thrombocytopenia—Doxorubicin—urinary bladder cancer	9.72e-05	0.000517	CcSEcCtD
Oxaprozin—Insomnia—Epirubicin—urinary bladder cancer	9.71e-05	0.000516	CcSEcCtD
Oxaprozin—Tachycardia—Doxorubicin—urinary bladder cancer	9.69e-05	0.000515	CcSEcCtD
Oxaprozin—Paraesthesia—Epirubicin—urinary bladder cancer	9.64e-05	0.000513	CcSEcCtD
Oxaprozin—CYP2C9—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	9.63e-05	0.00248	CbGpPWpGaD
Oxaprozin—Hyperhidrosis—Doxorubicin—urinary bladder cancer	9.6e-05	0.000511	CcSEcCtD
Oxaprozin—Dyspnoea—Epirubicin—urinary bladder cancer	9.57e-05	0.000509	CcSEcCtD
Oxaprozin—Somnolence—Epirubicin—urinary bladder cancer	9.54e-05	0.000507	CcSEcCtD
Oxaprozin—Anorexia—Doxorubicin—urinary bladder cancer	9.47e-05	0.000503	CcSEcCtD
Oxaprozin—Feeling abnormal—Methotrexate—urinary bladder cancer	9.45e-05	0.000503	CcSEcCtD
Oxaprozin—Dyspepsia—Epirubicin—urinary bladder cancer	9.45e-05	0.000502	CcSEcCtD
Oxaprozin—Gastrointestinal pain—Methotrexate—urinary bladder cancer	9.38e-05	0.000499	CcSEcCtD
Oxaprozin—Decreased appetite—Epirubicin—urinary bladder cancer	9.33e-05	0.000496	CcSEcCtD
Oxaprozin—Hypotension—Doxorubicin—urinary bladder cancer	9.28e-05	0.000493	CcSEcCtD
Oxaprozin—Constipation—Epirubicin—urinary bladder cancer	9.18e-05	0.000488	CcSEcCtD
Oxaprozin—Urticaria—Methotrexate—urinary bladder cancer	9.11e-05	0.000485	CcSEcCtD
Oxaprozin—PTGS2—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	9.1e-05	0.00234	CbGpPWpGaD
Oxaprozin—Abdominal pain—Methotrexate—urinary bladder cancer	9.07e-05	0.000482	CcSEcCtD
Oxaprozin—Body temperature increased—Methotrexate—urinary bladder cancer	9.07e-05	0.000482	CcSEcCtD
Oxaprozin—Insomnia—Doxorubicin—urinary bladder cancer	8.98e-05	0.000478	CcSEcCtD
Oxaprozin—PTGS2—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	8.93e-05	0.0023	CbGpPWpGaD
Oxaprozin—Paraesthesia—Doxorubicin—urinary bladder cancer	8.92e-05	0.000474	CcSEcCtD
Oxaprozin—PTGS2—Spinal Cord Injury—RB1—urinary bladder cancer	8.9e-05	0.00229	CbGpPWpGaD
Oxaprozin—Dyspnoea—Doxorubicin—urinary bladder cancer	8.85e-05	0.000471	CcSEcCtD
Oxaprozin—PTGS2—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	8.85e-05	0.00228	CbGpPWpGaD
Oxaprozin—Feeling abnormal—Epirubicin—urinary bladder cancer	8.84e-05	0.00047	CcSEcCtD
Oxaprozin—Somnolence—Doxorubicin—urinary bladder cancer	8.83e-05	0.00047	CcSEcCtD
Oxaprozin—Gastrointestinal pain—Epirubicin—urinary bladder cancer	8.78e-05	0.000467	CcSEcCtD
Oxaprozin—Dyspepsia—Doxorubicin—urinary bladder cancer	8.74e-05	0.000465	CcSEcCtD
Oxaprozin—PTGS2—C-MYB transcription factor network—CCND1—urinary bladder cancer	8.68e-05	0.00224	CbGpPWpGaD
Oxaprozin—Decreased appetite—Doxorubicin—urinary bladder cancer	8.63e-05	0.000459	CcSEcCtD
Oxaprozin—Urticaria—Epirubicin—urinary bladder cancer	8.53e-05	0.000453	CcSEcCtD
Oxaprozin—Constipation—Doxorubicin—urinary bladder cancer	8.49e-05	0.000452	CcSEcCtD
Oxaprozin—Abdominal pain—Epirubicin—urinary bladder cancer	8.48e-05	0.000451	CcSEcCtD
Oxaprozin—Body temperature increased—Epirubicin—urinary bladder cancer	8.48e-05	0.000451	CcSEcCtD
Oxaprozin—PTGS2—C-MYB transcription factor network—CDKN1A—urinary bladder cancer	8.4e-05	0.00216	CbGpPWpGaD
Oxaprozin—Asthenia—Methotrexate—urinary bladder cancer	8.23e-05	0.000438	CcSEcCtD
Oxaprozin—Feeling abnormal—Doxorubicin—urinary bladder cancer	8.18e-05	0.000435	CcSEcCtD
Oxaprozin—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	8.12e-05	0.000432	CcSEcCtD
Oxaprozin—Pruritus—Methotrexate—urinary bladder cancer	8.11e-05	0.000432	CcSEcCtD
Oxaprozin—PTGS2—Spinal Cord Injury—RHOA—urinary bladder cancer	8.09e-05	0.00208	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—GSTZ1—urinary bladder cancer	8.06e-05	0.00208	CbGpPWpGaD
Oxaprozin—PTGS2—C-MYB transcription factor network—EP300—urinary bladder cancer	7.99e-05	0.00206	CbGpPWpGaD
Oxaprozin—PTGS2—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	7.92e-05	0.00204	CbGpPWpGaD
Oxaprozin—Urticaria—Doxorubicin—urinary bladder cancer	7.89e-05	0.00042	CcSEcCtD
Oxaprozin—PTGS1—Selenium Micronutrient Network—TNF—urinary bladder cancer	7.87e-05	0.00203	CbGpPWpGaD
Oxaprozin—Abdominal pain—Doxorubicin—urinary bladder cancer	7.85e-05	0.000417	CcSEcCtD
Oxaprozin—Body temperature increased—Doxorubicin—urinary bladder cancer	7.85e-05	0.000417	CcSEcCtD
Oxaprozin—Diarrhoea—Methotrexate—urinary bladder cancer	7.85e-05	0.000417	CcSEcCtD
Oxaprozin—Asthenia—Epirubicin—urinary bladder cancer	7.7e-05	0.00041	CcSEcCtD
Oxaprozin—PTGS1—Metabolism—NAT1—urinary bladder cancer	7.65e-05	0.00197	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—GSTO2—urinary bladder cancer	7.65e-05	0.00197	CbGpPWpGaD
Oxaprozin—Pruritus—Epirubicin—urinary bladder cancer	7.59e-05	0.000404	CcSEcCtD
Oxaprozin—Dizziness—Methotrexate—urinary bladder cancer	7.58e-05	0.000403	CcSEcCtD
Oxaprozin—PTGS1—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	7.52e-05	0.00194	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	7.43e-05	0.00191	CbGpPWpGaD
Oxaprozin—Diarrhoea—Epirubicin—urinary bladder cancer	7.34e-05	0.000391	CcSEcCtD
Oxaprozin—Vomiting—Methotrexate—urinary bladder cancer	7.29e-05	0.000388	CcSEcCtD
Oxaprozin—PTGS2—Disease—GSTO2—urinary bladder cancer	7.25e-05	0.00187	CbGpPWpGaD
Oxaprozin—Rash—Methotrexate—urinary bladder cancer	7.23e-05	0.000385	CcSEcCtD
Oxaprozin—Dermatitis—Methotrexate—urinary bladder cancer	7.22e-05	0.000384	CcSEcCtD
Oxaprozin—Headache—Methotrexate—urinary bladder cancer	7.18e-05	0.000382	CcSEcCtD
Oxaprozin—Asthenia—Doxorubicin—urinary bladder cancer	7.12e-05	0.000379	CcSEcCtD
Oxaprozin—PTGS2—Spinal Cord Injury—CXCL8—urinary bladder cancer	7.1e-05	0.00183	CbGpPWpGaD
Oxaprozin—Dizziness—Epirubicin—urinary bladder cancer	7.1e-05	0.000377	CcSEcCtD
Oxaprozin—Pruritus—Doxorubicin—urinary bladder cancer	7.03e-05	0.000374	CcSEcCtD
Oxaprozin—PTGS2—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	7e-05	0.0018	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—UGT2B7—urinary bladder cancer	6.99e-05	0.0018	CbGpPWpGaD
Oxaprozin—PTGS2—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	6.97e-05	0.00179	CbGpPWpGaD
Oxaprozin—PTGS2—C-MYB transcription factor network—MYC—urinary bladder cancer	6.96e-05	0.00179	CbGpPWpGaD
Oxaprozin—PTGS2—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	6.94e-05	0.00179	CbGpPWpGaD
Oxaprozin—CYP2C9—Biological oxidations—GSTP1—urinary bladder cancer	6.92e-05	0.00178	CbGpPWpGaD
Oxaprozin—CYP2C9—Metapathway biotransformation—GSTP1—urinary bladder cancer	6.83e-05	0.00176	CbGpPWpGaD
Oxaprozin—Vomiting—Epirubicin—urinary bladder cancer	6.82e-05	0.000363	CcSEcCtD
Oxaprozin—Nausea—Methotrexate—urinary bladder cancer	6.81e-05	0.000362	CcSEcCtD
Oxaprozin—Diarrhoea—Doxorubicin—urinary bladder cancer	6.79e-05	0.000361	CcSEcCtD
Oxaprozin—PTGS2—Spinal Cord Injury—IL2—urinary bladder cancer	6.78e-05	0.00175	CbGpPWpGaD
Oxaprozin—Rash—Epirubicin—urinary bladder cancer	6.77e-05	0.00036	CcSEcCtD
Oxaprozin—Dermatitis—Epirubicin—urinary bladder cancer	6.76e-05	0.00036	CcSEcCtD
Oxaprozin—Headache—Epirubicin—urinary bladder cancer	6.72e-05	0.000358	CcSEcCtD
Oxaprozin—PTGS2—Spinal Cord Injury—CCND1—urinary bladder cancer	6.61e-05	0.0017	CbGpPWpGaD
Oxaprozin—Dizziness—Doxorubicin—urinary bladder cancer	6.57e-05	0.000349	CcSEcCtD
Oxaprozin—PTGS2—C-MYB transcription factor network—KRAS—urinary bladder cancer	6.43e-05	0.00166	CbGpPWpGaD
Oxaprozin—PTGS2—Spinal Cord Injury—MMP9—urinary bladder cancer	6.42e-05	0.00165	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—GSTZ1—urinary bladder cancer	6.4e-05	0.00165	CbGpPWpGaD
Oxaprozin—Nausea—Epirubicin—urinary bladder cancer	6.38e-05	0.000339	CcSEcCtD
Oxaprozin—CYP2C9—Biological oxidations—GSTM1—urinary bladder cancer	6.36e-05	0.00164	CbGpPWpGaD
Oxaprozin—Vomiting—Doxorubicin—urinary bladder cancer	6.31e-05	0.000336	CcSEcCtD
Oxaprozin—PTGS1—Metabolism—CYP4B1—urinary bladder cancer	6.3e-05	0.00162	CbGpPWpGaD
Oxaprozin—CYP2C9—Metapathway biotransformation—GSTM1—urinary bladder cancer	6.27e-05	0.00162	CbGpPWpGaD
Oxaprozin—Rash—Doxorubicin—urinary bladder cancer	6.26e-05	0.000333	CcSEcCtD
Oxaprozin—Dermatitis—Doxorubicin—urinary bladder cancer	6.26e-05	0.000333	CcSEcCtD
Oxaprozin—PTGS2—Selenium Micronutrient Network—TNF—urinary bladder cancer	6.25e-05	0.00161	CbGpPWpGaD
Oxaprozin—Headache—Doxorubicin—urinary bladder cancer	6.22e-05	0.000331	CcSEcCtD
Oxaprozin—PTGS2—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	6.08e-05	0.00157	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—GSTO2—urinary bladder cancer	6.07e-05	0.00156	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—NAT1—urinary bladder cancer	6.07e-05	0.00156	CbGpPWpGaD
Oxaprozin—PTGS2—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	6e-05	0.00155	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	5.97e-05	0.00154	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—SLC19A1—urinary bladder cancer	5.95e-05	0.00153	CbGpPWpGaD
Oxaprozin—Nausea—Doxorubicin—urinary bladder cancer	5.9e-05	0.000314	CcSEcCtD
Oxaprozin—PTGS1—Metabolism—PRSS3—urinary bladder cancer	5.79e-05	0.00149	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—SLC19A1—urinary bladder cancer	5.64e-05	0.00145	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—UGT2B7—urinary bladder cancer	5.55e-05	0.00143	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—PRSS3—urinary bladder cancer	5.49e-05	0.00141	CbGpPWpGaD
Oxaprozin—PTGS2—C-MYB transcription factor network—HRAS—urinary bladder cancer	5.47e-05	0.00141	CbGpPWpGaD
Oxaprozin—PTGS2—Spinal Cord Injury—MYC—urinary bladder cancer	5.3e-05	0.00137	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—HDAC4—urinary bladder cancer	5.24e-05	0.00135	CbGpPWpGaD
Oxaprozin—PTGS2—Spinal Cord Injury—EGFR—urinary bladder cancer	5.19e-05	0.00134	CbGpPWpGaD
Oxaprozin—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	5.09e-05	0.00131	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—CYP4B1—urinary bladder cancer	5e-05	0.00129	CbGpPWpGaD
Oxaprozin—PTGS2—Spinal Cord Injury—TNF—urinary bladder cancer	4.94e-05	0.00127	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—SLC19A1—urinary bladder cancer	4.72e-05	0.00122	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	4.65e-05	0.0012	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—TYMP—urinary bladder cancer	4.63e-05	0.00119	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—PRSS3—urinary bladder cancer	4.6e-05	0.00118	CbGpPWpGaD
Oxaprozin—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	4.5e-05	0.00116	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	4.45e-05	0.00115	CbGpPWpGaD
Oxaprozin—PTGS2—Spinal Cord Injury—TP53—urinary bladder cancer	4.36e-05	0.00112	CbGpPWpGaD
Oxaprozin—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	4.35e-05	0.00112	CbGpPWpGaD
Oxaprozin—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	4.34e-05	0.00112	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	4.24e-05	0.00109	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—NAT2—urinary bladder cancer	4.19e-05	0.00108	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—LIG1—urinary bladder cancer	4.16e-05	0.00107	CbGpPWpGaD
Oxaprozin—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	4.14e-05	0.00107	CbGpPWpGaD
Oxaprozin—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	4.03e-05	0.00104	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	4.02e-05	0.00104	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—NAT1—urinary bladder cancer	4.02e-05	0.00104	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	3.95e-05	0.00102	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	3.69e-05	0.00095	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—TYMP—urinary bladder cancer	3.68e-05	0.000947	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	3.68e-05	0.000947	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—RRM2—urinary bladder cancer	3.62e-05	0.000931	CbGpPWpGaD
Oxaprozin—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	3.61e-05	0.000929	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.53e-05	0.00091	CbGpPWpGaD
Oxaprozin—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	3.53e-05	0.000909	CbGpPWpGaD
Oxaprozin—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	3.36e-05	0.000866	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—HPGDS—urinary bladder cancer	3.35e-05	0.000863	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—ENO2—urinary bladder cancer	3.35e-05	0.000863	CbGpPWpGaD
Oxaprozin—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	3.33e-05	0.000859	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.33e-05	0.000858	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—NAT2—urinary bladder cancer	3.33e-05	0.000857	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	3.31e-05	0.000853	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—GSTT1—urinary bladder cancer	3.25e-05	0.000837	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.2e-05	0.000824	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—ENO2—urinary bladder cancer	3.17e-05	0.000818	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	3.13e-05	0.000805	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	3.05e-05	0.000785	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—RBX1—urinary bladder cancer	3.01e-05	0.000775	CbGpPWpGaD
Oxaprozin—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	2.96e-05	0.000763	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—RRM2—urinary bladder cancer	2.87e-05	0.000739	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—NQO1—urinary bladder cancer	2.7e-05	0.000695	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—JAG1—urinary bladder cancer	2.69e-05	0.000694	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—ENO2—urinary bladder cancer	2.66e-05	0.000685	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—HPGDS—urinary bladder cancer	2.66e-05	0.000685	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.64e-05	0.000681	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.62e-05	0.000675	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—GSTT1—urinary bladder cancer	2.58e-05	0.000664	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.54e-05	0.000654	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.44e-05	0.000629	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—TYMP—urinary bladder cancer	2.44e-05	0.000627	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.34e-05	0.000602	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.28e-05	0.000588	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—GSTP1—urinary bladder cancer	2.25e-05	0.00058	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—NAT2—urinary bladder cancer	2.2e-05	0.000567	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.18e-05	0.000561	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—NQO1—urinary bladder cancer	2.14e-05	0.000552	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—TYMS—urinary bladder cancer	2.09e-05	0.000539	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—GSTM1—urinary bladder cancer	2.07e-05	0.000533	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—NCOR1—urinary bladder cancer	2.07e-05	0.000533	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—GPX1—urinary bladder cancer	1.98e-05	0.00051	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—NCOR1—urinary bladder cancer	1.96e-05	0.000505	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—ERCC2—urinary bladder cancer	1.95e-05	0.000501	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—RRM2—urinary bladder cancer	1.9e-05	0.00049	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—ERCC2—urinary bladder cancer	1.84e-05	0.000475	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—MTHFR—urinary bladder cancer	1.83e-05	0.000471	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.81e-05	0.000467	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—GSTP1—urinary bladder cancer	1.79e-05	0.00046	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—ENO2—urinary bladder cancer	1.76e-05	0.000453	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	1.76e-05	0.000453	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.75e-05	0.000451	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—MTHFR—urinary bladder cancer	1.73e-05	0.000446	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.73e-05	0.000445	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—TERT—urinary bladder cancer	1.73e-05	0.000445	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	1.71e-05	0.00044	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.68e-05	0.000433	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—TYMS—urinary bladder cancer	1.66e-05	0.000428	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—NCOR1—urinary bladder cancer	1.64e-05	0.000423	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—GSTM1—urinary bladder cancer	1.64e-05	0.000423	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—FGFR3—urinary bladder cancer	1.59e-05	0.000409	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—GPX1—urinary bladder cancer	1.57e-05	0.000405	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—ERCC2—urinary bladder cancer	1.54e-05	0.000398	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—PPARG—urinary bladder cancer	1.48e-05	0.000382	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—MTHFR—urinary bladder cancer	1.45e-05	0.000374	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—CREBBP—urinary bladder cancer	1.42e-05	0.000367	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—NQO1—urinary bladder cancer	1.42e-05	0.000366	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.38e-05	0.000355	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—CREBBP—urinary bladder cancer	1.35e-05	0.000348	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—RHOA—urinary bladder cancer	1.22e-05	0.000315	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.2e-05	0.000309	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	1.18e-05	0.000305	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—PPARG—urinary bladder cancer	1.18e-05	0.000303	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—PTGS2—urinary bladder cancer	1.17e-05	0.0003	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.15e-05	0.000295	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—CREBBP—urinary bladder cancer	1.13e-05	0.000291	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—ERBB2—urinary bladder cancer	1.13e-05	0.000291	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—TYMS—urinary bladder cancer	1.1e-05	0.000283	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	1.09e-05	0.00028	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	1.09e-05	0.00028	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—GPX1—urinary bladder cancer	1.04e-05	0.000268	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	1.02e-05	0.000263	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—PTEN—urinary bladder cancer	1.02e-05	0.000262	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—EP300—urinary bladder cancer	9.7e-06	0.00025	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—CDKN1A—urinary bladder cancer	9.66e-06	0.000249	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—PTEN—urinary bladder cancer	9.64e-06	0.000248	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	9.61e-06	0.000248	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—EP300—urinary bladder cancer	9.2e-06	0.000237	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—SRC—urinary bladder cancer	8.94e-06	0.00023	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—PTEN—urinary bladder cancer	8.07e-06	0.000208	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—MYC—urinary bladder cancer	8.01e-06	0.000206	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—EGFR—urinary bladder cancer	7.84e-06	0.000202	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—PPARG—urinary bladder cancer	7.79e-06	0.000201	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—EP300—urinary bladder cancer	7.7e-06	0.000198	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	7.49e-06	0.000193	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—KRAS—urinary bladder cancer	7.4e-06	0.000191	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—HRAS—urinary bladder cancer	6.29e-06	0.000162	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	6.13e-06	0.000158	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—PTEN—urinary bladder cancer	5.35e-06	0.000138	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—EP300—urinary bladder cancer	5.1e-06	0.000131	CbGpPWpGaD
